EuroSIDA Publications 2022
 
  1. Integrase Strand Transfer Inhibitor Use and Cancer Incidence in a Large Cohort Setting. Greenberg L, Ryom L, Neesgaard B, Miró JM, Dahlerup Rasmussen L, Zangerle R, Grabmeier-Pfistershammer K, Günthard HF, Kusejko K, Smith C, Mussini C, Menozzi M, Wit F, Van Der Valk M, d'Arminio Monforte A, De Wit S, Necsoi C, Pelchen-Matthews A, Lundgren J, Peters L, Castagna A, Muccini C, Vehreschild JJ, Pradier C, Bruguera Riera A, Sönnerborg A, Petoumenos K, Garges H, Rogatto F, Dedes N, Bansi-Matharu L, Mocroft A; RESPOND Study Group.
    Open Forum Infect Dis. 2022;9(3):ofac029. Abstract
     
  2. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. Byonanebye DM, Polizzotto MN, Neesgaard B, Sarcletti M, Matulionyte R, Braun DL, Castagna A, de Wit S, Wit F, Fontas E, Vehreschild JJ, Vesterbacka J, Greenberg L, Hatleberg C, Garges H, Gallant J, Volny Anne A, Öllinger A, Mozer-Lisewska I, Surial B, Spagnuolo V, Necsoi C, van der Valk M, Mocroft A, Law M, Ryom L, Petoumenos K; RESPOND study group.
    HIV Med. 2022. Epub ahead of print. Abstract
     
  3. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium Neesgaard B, Greenberg L, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-Matthews A, Mussini C, Castagna A, Pradier C, d'Arminio Monforte A, Vehreschild JJ, Sönnerborg A, Anne AV, Carr A, Bansi-Matharu L, Lundgren JD, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Necsoi C, van der Valk M, Menozzi M, Muccini C, Peters L, Mocroft A, Ryom L.
    Lancet HIV. 2022:S2352-3018(22)00094-7. Abstract
     
  4. Observational cohort study of rilpivirine (RPV) utilization in Europe. Cozzi-Lepri A, Peters L, Pelchen-Matthews A, Neesgaard B, De Wit S, Johansen IS, Edwards S, Stephan C, Adamis G, Staub T, Zagalo A, Domingo P, Elbirt D, Kusejko K, Brännström J, Paduta D, Trofimova T, Szlavik J, Zilmer K, Losso M, Van Eygen V, Pai H, Lundgren J, Mocroft A; EuroSIDA Study Group.
    AIDS Res Ther. 2022;19(1):38. Abstract
     
  5. Use of contraindicated antiretroviral drugs in people with HIV/HCV coinfections receiving HCV treatment with direct-acting antivirals-Results from the EuroSIDA study. Nikolaichuk M, Mocroft A, Wandeler G, Szlavik J, Gottfredsson M, Reikvam DH, Svedhem V, Elinav H, Laguno M, Mansinho K, Devitt E, Chkhartishvili N, Behrens G, Bogner J, Viard JP, Winston A, Benfield T, Leen C, Fursa O, Rockstroh J, Peters L; EuroSIDA study group.
    HIV Med. 2022. Epub ahead of print. Abstract
     
  6. Changes in body mass index and clinical outcomes after initiation of contemporary antiretroviral regimens. Bannister WP, Mast TC, de Wit S, Gerstoft J, Wiese L, Milinkovic A, Hadziosmanovic V, Clarke A, Rasmussen LD, Lacombe K, Schommers P, Staub T, Zagalo A, Portu JJ, Tau L, Calmy A, Cavassini M, Gisinger M, Borodulina E, Mocroft A, Reekie J, Peters L; EuroSIDA study group.
    AIDS. 2022. Epub ahead of print. Abstract
     
  7. Recent abacavir use and incident cardiovascular disease in contemporary treated people living with HIV. Jaschinski N, Greenberg L, Neesgaard B, Miró JM, Grabmeier-Pfistershammer K, Wandeler G, Smith C, De Wit S, Wit F, Pelchen-Matthews A, Mussini C, Castagna A, Pradier C, Monforte A, Vehreschild J, Sönnerborg A, Anne AV, Carr A, Bansi-Matharu L, Lundgren J, Garges H, Rogatto F, Zangerle R, Günthard HF, Rasmussen LD, Nescoi C, Van Der Valk M, Menozzi M, Muccini C, Mocroft A, Peters L, Ryom L; RESPOND Study Group.
    AIDS. 2022. Epub ahead of print. Abstract
     
Total publications September 2022: 327

 

​IN PRESS

  1. Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in persons living with HIV. Erich S. Tusch, Lene Ryom, Olga Fursa, Lars Peters, Lars Oestergaard, Eric Florence, Simon Edwards, Christian Hoffmann, Helen Sambatakou, Peter Reiss, Eduardo Shahar, Dag Henrik Reikvam, Brigitte Schmied, Dzmitry Paduta, Alexei Yakovlev, János Szlávik, Jovan Ranin, Kai Zilmer, Vilma Uždaviniene, Annegret Pelchen-Matthews, Amanda Mocroft, Joanne Reekie for the EuroSIDA Study Group.
    AIDS. 2022
     
  2. The role of HIV/HBV/HCVRNA+ triple infection in end-stage liver disease and all-cause mortality in Europe. Amanda MOCROFT for the EuroSIDA study group.
    AIDS, 2022
     
  3. Long-term trends of alanine aminotransferase levels among persons living with human immunodeficiency virus/hepatitis B virus with and without hepatitis delta coinfection Begré Lorin, Béguelin Charles, Boyd Anders, Peters Lars, Rockstroh Jürgen, Günthard Huldrych F., Bernasconi Enos, Cavassini Matthias, Lacombe Karine, Mocroft Amanda, Wandeler Gilles, Rauch Andri.
    Frontiers in Medicine, 2022
     
  4. Low risk of failing direct-acting antivirals in people with HIV/HCV from Sub-Saharan Africa or Southeastern Asia: a European cross-sectional study. Cas Isfordink, Anders Boyd, Amanda Mocroft, Katharina Kusejko, Colette Smit, Stephane de Wit, Tabitha Mahungu, Karolin Falconer, Gilles Wandeler, Matthias Cavassini, Marcel Stöckle, Janke Schinkel, Andri Rauch, Lars Peters, Marc van der Valk, on behalf of EuroSIDA, the Swiss HIV Cohort Study and the ATHENA observational cohort Open Forum Infectious Diseases, 2022